Literature DB >> 16572283

Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.

Sumeet Agrawal1, Ramnath Misra, Amita Aggarwal.   

Abstract

INTRODUCTION: Autoantibodies in rheumatoid arthritis (RA) are useful both for diagnosis and prognosis. Antibodies directed against citrullinated antigens have recently been shown to predict development of RA as well as poor outcome in early arthritis. Data on their role in established RA is limited. We studied the association of various autoantibodies in RA with its severity.
MATERIALS AND METHODS: A total of one hundred and twenty nine-patients with established RA was enrolled and sera were collected and stored at -70 degrees C. Data regarding erosions, deformities, and extra-articular features were collected. IgM rheumatoid factor (RF) was measured using nephelometry and value above 20 U was considered positive. IgA RF was measured by enzyme-linked immunosorbent assay (ELISA) and value above the mean+/-2 SD of normal healthy control was taken as positive. Anti-keratin antibody (AKA) was detected by indirect immunofluorescence assay using rat esophagus as substrate. Anti-cyclic citrullinated peptide (CCP) antibodies were measured by commercial ELISA and a value above 5 U was considered as positive.
RESULTS: The prevalence of various autoantibodies was: IgM RF 82.2%, anti-CCP antibodies 82.2%, AKA 51.9%, and anti IgA RF 45%. The concordance rate of anti-CCP antibodies with IgM RF was 83%, with AKA 68%, and with IgA RF 60.5%. All but one patient positive for AKA were positive for anti-CCP antibodies. The presence of IgM RF, AKA, and anti-CCP antibody was associated with joint erosions and deformities. None of the antibodies had any association with presence of extra-articular features. No association of IgA RF was seen with erosions, deformities, or extra-articular features. Among 23 seronegative RA patients, 11 were positive for anti-CCP antibodies and 6 were AKA positive. The presence of anti-CCP antibodies was associated with presence of deformities (p<0.05).
CONCLUSION: Anti-CCP antibodies are present in majority of patients with established RA including seronegative patients. Both anti-CCP and AKA, in addition to conventional marker like IgM RF, are associated with severe erosive disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572283     DOI: 10.1007/s10067-006-0275-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Clinical relevance of IgA rheumatoid factor (RF) in children with juvenile rheumatoid arthritis.

Authors:  A Bharadwaj; A Aggarwal; R Misra
Journal:  Rheumatol Int       Date:  1999       Impact factor: 2.631

2.  Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis.

Authors:  S Bas; S Genevay; O Meyer; C Gabay
Journal:  Rheumatology (Oxford)       Date:  2003-05       Impact factor: 7.580

3.  Early rheumatoid arthritis--onset, course, and outcome over 2 years.

Authors:  K B Eberhardt; L C Rydgren; H Pettersson; F A Wollheim
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

4.  Anti-keratin antibodies in patients with rheumatoid arthritis.

Authors:  B L Sharma; R Rani; R Misra; A Aggarwal
Journal:  Indian J Med Res       Date:  2000-06       Impact factor: 2.375

5.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

Authors:  G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

6.  Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis.

Authors:  L Paimela; M Gripenberg; P Kurki; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

7.  Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease.

Authors:  P Kurki; K Aho; T Palosuo; M Heliövaara
Journal:  Arthritis Rheum       Date:  1992-08

8.  Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor.

Authors:  I Teitsson; R H Withrington; M H Seifert; H Valdimarsson
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

9.  Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage.

Authors:  B Combe; J F Eliaou; J P Daurès; O Meyer; J Clot; J Sany
Journal:  Br J Rheumatol       Date:  1995-06

10.  Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations.

Authors:  L De Rycke; I Peene; I E A Hoffman; E Kruithof; A Union; L Meheus; K Lebeer; B Wyns; C Vincent; H Mielants; L Boullart; G Serre; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

View more
  33 in total

1.  The expression of PADI4 in synovium of rheumatoid arthritis.

Authors:  Xiaotian Chang; Yan Zhao; Shui Sun; Yunzhong Zhang; Youming Zhu
Journal:  Rheumatol Int       Date:  2009-02-08       Impact factor: 2.631

Review 2.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

3.  Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension.

Authors:  Lisa K Blum; Richard R L Cao; Andrew J Sweatt; Matthew Bill; Lauren J Lahey; Andrew C Hsi; Casey S Lee; Sarah Kongpachith; Chia-Hsin Ju; Rong Mao; Heidi H Wong; Mark R Nicolls; Roham T Zamanian; William H Robinson
Journal:  Eur J Immunol       Date:  2018-02-22       Impact factor: 5.532

4.  Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis.

Authors:  Laura C Cappelli; Judy Lynn Palmer; Joel Kremer; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2017-04-01       Impact factor: 5.532

5.  Serum levels of calreticulin in correlation with disease activity in patients with rheumatoid arthritis.

Authors:  Min Ni; Wei Wei; Yichao Wang; Na Zhang; Hongmei Ding; Chen Shen; Fang Zheng
Journal:  J Clin Immunol       Date:  2013-03-27       Impact factor: 8.317

6.  Association of anti-CCP positivity with serum ferritin and DAS-28.

Authors:  Burcu Önder; Aydan Kurtaran; Songül Kimyon; Barin Selçuk; Müfit Akyüz
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

7.  PADI4 and tumourigenesis.

Authors:  Xiaotian Chang; Kehua Fang
Journal:  Cancer Cell Int       Date:  2010-03-12       Impact factor: 5.722

8.  Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients?

Authors:  Nikolaos G Papadopoulos; Georgios Z Tsiaousis; Aikaterini Pavlitou-Tsiontsi; Anastasia Giannakou; Vassiliki K Galanopoulou
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 9.  Anti-citrullinated protein antibodies: role in pathogenesis of RA and potential as a diagnostic tool.

Authors:  Sadaf Moeez; Peter John; Attya Bhatti
Journal:  Rheumatol Int       Date:  2013-02-01       Impact factor: 2.631

Review 10.  Statin treatment for rheumatoid arthritis: a promising novel indication.

Authors:  Kosmas I Paraskevas
Journal:  Clin Rheumatol       Date:  2007-12-08       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.